Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer by Mischo, Axel et al.
Prospective study on the expression of cancer testis genes and antibody responses
in 100 consecutive patients with primary breast cancer
Axel Mischo1 , Boris Kubuschok1, Kubilay Ertan2, Klaus-Dieter Preuss1, Bernd Romeike3, Evi Regitz1, Claudia Schormann1,
Diederik de Bruijn4, Andreas Wadle1, Frank Neumann1, Werner Schmidt3, Christoph Renner1 and Michael Pfreundschuh1*
1Department of Internal Medicine I, University of Saarland Medical School, Homburg/Saar, Germany
2Obstetrics and Gynecology, University of Saarland Medical School, Homburg/Saar, Germany
3Neuropathology, University of Saarland Medical School, Homburg/Saar, Germany
4Department of Human Genetics, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands
To determine the expression of cancer testis (CT) genes and anti-
body responses in a nonselected population of patients with pri-
mary breast cancer, we investigated the composite expression of
11 CT genes by RT-PCR in fresh biopsies of 100 consecutive cases
of primary breast carcinoma and by immunohistology in selected
RT-PCR-positive cases. Antibody responses against 7 CT antigens
were analyzed using recombinant antigen expression on yeast sur-
face. In 98 evaluable cases, SCP-1 and SSX-4 were expressed most
frequently (both 65%), followed by HOM-TES-85/CT-8 (47%),
GAGE (26%), SSX-1 (20%), NY-ESO-1 (13%), MAGE-3 (11%),
SSX-2 (8%), CT-10 (7%), MAGE-4 (4%) and CT-7 (1%). One CT
gene was expressed by 90% of the cases; 79% expressed 2, 48%
3, 29% 4, 12% 5, 6% 6, 3% 7, 2% 8 and one case coex-
pressed 9 antigens. Of 100 serum samples screened for CT anti-
gen-speciﬁc antibodies, antibodies against NY-ESO-1 were
detected in 4 patients, against SCP-1 in 6 patients and against
SSX-2 in 1 patient, while no antibodies were detected against
MAGE-3, CT-7 and CT-10. Expression of CT genes or antibody
responses was not correlated with clinical parameters (meno-
pausal status, tumor size, nodal involvement, grading, histology
and estrogen receptor status) or the demonstration of CT gene
expression at the protein level, by immunohistology. Our results
show that breast carcinomas are among the tumors with the most
frequent expression of CT antigens, rendering many patients
potential candidates for vaccine trials.
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Breast cancer is one of the most common malignancies in
women and second in cancers causing death among women in the
United States, where over 40,000 patients die each year of the dis-
ease.1 Despite effective adjuvant therapy after primary surgery,2 a
considerable proportion of patients with limited-stage disease
develop metastatic disease. Even though the median survival of
patients with metastatic breast cancer can be prolonged by effec-
tive hormonal3 and chemotherapeutic4 agents as well as combina-
tions of chemotherapy with the anti-her-2/neu antibody trastuzu-
mab,5 metastatic disease is eventually fatal. An attractive
approach to reduce the rate of failures after primary treatment of
breast cancer could be immunotherapeutic strategies, which
should be most efﬁcient in the state of minimal residual disease
after primary treatment of patients with limited-stage disease.
A prerequisite for the development of tumor-speciﬁc immuno-
therapeutic strategies is the existence and identiﬁcation of tumor
antigens, i.e., genes that are either exclusively or preferentially
expressed in malignant compared to normal tissues. In breast can-
cer, only few tumor antigens are known, and most are overex-
pressed in tumor cells but will also be found at a certain level in
normal human cells, e.g., CEA, CA15-3, Her-2/neu, MUC-1.6,7
Expression of these genes in normal tissue limits their use as tar-
gets for speciﬁc immunotherapy. In contrast to the overexpressed
antigens, the so-called shared tumor antigens are expressed only
by a variety of malignant tumors, not by normal tissues except for
the germ cells in testis. Due to this peculiar expression proﬁle, the
terms CT8 and CG9 antigen have been coined for them. An impor-
tant point concerning the therapeutic use of CT antigens is that
vaccines targeting them will not affect germ cells because they
lack expression of the MHC molecules that are necessary for the
presentation of the respective antigenic peptides. The group of CT
antigens includes the CTL-reactive MAGE,10 BAGE11 and
GAGE12 families, as well as HOM-MEL-40/SSX-2,13 the
other SSX family members,14 NY-ESO-1,8 HOM-TES-14/SCP-1,15
CT-7,16 HOM-TES-85/CT-817 and CT-10,8 all of which have been
deﬁned using SEREX.18 Analysis of the expression pattern of the
CT genes revealed that some of them are also expressed in breast
cancer.19,20 However, little is known about the composite expres-
sion of CT genes in primary breast cancer, and no data are avail-
able on the incidence of antibodies against these antigens in breast
cancer. Our study of a large panel of CT genes in primary breast
cancer shows that these tumors frequently express a selected spec-
trum of CT genes, providing the molecular basis for the develop-
ment of CT antigen–based vaccine strategies.
Material and methods
Tissues and cell lines
The study was approved by the local ethics review board
(Ethikkommission der €Arztekammer des Saarlandes) and per-
formed according to the Declaration of Helsinki. Recombinant
DNA work was done with ofﬁcial permission and in accordance
with the rules of the state government of Saarland. After informed
consent, tumor and serum samples were obtained from 100
patients with operable breast cancer upon the primary deﬁnitive
operation (mastectomy, 36 cases; lumpectomy, 59 cases; reductive
tumor surgery, 5 cases) at the Department of Gynecology, Univer-
sity of Saarland Medical School, between June 2001 and May
2002. Biopsy samples were snap-frozen within 1 hr after excision.
Tumor stage and grading were determined according to the
UICC.21 Breast cancer tissue was divided in 2 parts. One part was
ﬁxed in formalin and embedded in parafﬁn for conventional histo-
pathologic staining (hematoxylin and eosin) and immunohisto-
chemistry. The other part was snap-frozen in liquid nitrogen and
microscopically checked for the presence of neoplastic tissue and
the amount of contaminating normal breast tissue in cryostat sec-
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tions before use for RT-PCR. Normal tissues were collected from
breast-reduction operations performed for cosmetic reasons.
RT-PCR
Total cellular RNA was extracted from frozen tissue specimens
of 100 fresh breast cancer samples, 4 normal breast tissues
(obtained from breast-reduction operations) and other normal tis-
sues (see Results) using guanidinium-isothiocyanate for denatura-
tion followed by an acidic phenol extraction and isopropanol pre-
cipitation.18 Total RNA (4 lg) was primed with an oligo(dT)18
oligonucleotide and reverse-transcribed with Superscript II (Life
Technologies, Eggenstein, Germany) according to the manufac-
turer’s instructions. The cDNA obtained was tested for integrity
by ampliﬁcation of b-actin and p53 transcripts in a 35-cycle PCR,
as described elsewhere.22 For PCR analysis of the expression of
individual CT gene transcripts, ﬁrst-strand cDNA was ampliﬁed
with transcript-speciﬁc oligonucleotides (10 lmol) using 1 unit of
AmpliTaq Gold (Perkin Elmer, Weiterstadt, Germany), 10 nmol
of each deoxynucleotide triphosphate (dATP, dTTP, dCTP, dGTP)
and 1.67 mM MgCl2 in a 30 ll reaction. The primers (MWG Bio-
tech, Ebersberg, Germany) for the respective CT genes have been
reported previously20,23,24 and were as follows: SSX-1 50 (50-CTA
AAG CAT CAG AGA AGA GAA GC) and SSX-1 30 (50-AGA
TCT CTT ATT AAT CTT CTC AGA AA), annealing temperature
56C; SSX-2 50 (50-GTG CTC AAA TAC CAG AGA AGA TC)
and SSX-2 30 (50-TTT TGG GTC CAG ATC TCT CGT G),
annealing temperature 67C; SSX-4 50 (50-AAA TCG TCT ATG
TGT ATA TGA AGC T) and SSX-4 30 (50-GGG TCG CTG ATC
TCT TCA TAA AC) primers, annealing temperature 60C; SCP-1
50 (50-GTA CAG CAG AAA GCA AGC AAC TGA ATG) and
SCP-1 30 (50-GAA GGA ACT GCT TTA GAA TCC AAT TTC
C) primers, annealing temperature 60C; HOM-TES-85/CT-8 50
(50-GGA GAG GCT ACT CAA GAT GCA GAA GC) and HOM-
TES-85/CT-8 30 (50-CTG AGT GAC TAT GAG ATC TCT CTG)
primers, annealing temperature 64C; NY-ESO-1a 50 (50-AGT
TCT ACC TCG CCA TGC CT-30) and 30 (50-TCC TCC TCC
AGC GAC AAA CAA-30); NY-ESO-1b 50 (50-ATG GAT GCT
GCA GAT GCG G-30) and 30 (50-GCTTAGCGCCTCTGCCCTG-
30), annealing temperature 60C; MAGE-3 50 (50-TGG AGG ACC
AGA GGC CCC C) and MAGE-3 30 (50-GGA CGA TTA TCA
GGA GGC CTG C), annealing temperature 62C; MAGE-4 50 (50-
GAG CAG ACA GGC CAA CCG) and MAGE-4 30 (30-AAG
GAC TCT GCG TCA GGC), annealing temperature 67C; GAGE
50 (50-AGA CGC TAC GTA GAG CCT) and GAGE 30 (50-CCA
TCA GGA CCA TCT TCA) primers, annealing temperature
63C; CT-7 50 (50-CGG AGG GAG GAG ACT TA), sense, and
CT-7 30 (50-TTA AGG TGG TGC TCT AGG), antisense, anneal-
ing temperature 61C; CT-10 50 (50-CGG ATC GAA GGC ATT
TGT GAG-30) and 30 (50-GTG AAC TCA CGG GCT CTC TTG
AG-30), annealing temperature 55C.
Ampliﬁcation was performed in a TRIO-Thermoblock (Biometra,
Gottingen, Germany). After 12 min activation of AmpliTaq Gold
polymerase at 94C for hot-start induction, 35 cycles of PCR were
performed with 1 min at the respective annealing temperature as indi-
cated above, 2 min at 72C and 1 min at 94C, with a ﬁnal elongation
step at 72C for 8 min. A 15 ll aliquot of each reaction was size-frac-
tionated on a 2% agarose gel, visualized by ethidium bromide stain-
ing and assessed for products of the expected size.
Detection of antibodies against CT antigens
Patient sera were studied for antibodies against CT antigens by
ﬂow cytometry using yeast transformed to express the recombinant
antigen on the surface. RAYS was performed as described previ-
ously.25 The pYD1 plasmid was part of the pYD1 yeast display vec-
tor kit from Invitrogen (Leiden, Netherlands). cDNA coding for the
analyzed CT antigens was ampliﬁed by PCR from phage supernatant.
Primers (MWG Biotech) were as follows: NY-ESO-1 50 (50-GGG
GAA TTC CAG GCC GAA GGC CGG GGG CAC) and NY-ESO-1
30 (50-GGG CTC GAG TTA GCG CCT CTG CCC TGA GGG);
SSX-2 and SSX-4 50 (50-GGG GGG GAA TTC AAC GGA GAC
GAC GCC TTT G) and SSX-2 and SSX-4 30 (50-CTA CTC GAG
TTA CTC GTC ATC TTC CTC AGG GTC);MAGE-A3 50 (50-GGG
GGC AAT TGC CTC TTG AGC AGA GGA GTC AGC AC) and
MAGE-A3 30 (50-GGG GCT CGA GTC ATC CTT CCC CCT CTC
TCA AAA CC); CT-7 50 (50-CCA AAG AAT TCG GCA CAA TTG
CCT CAG GGG) and CT-7 30 (50-GGG CTC GAG TCA CTC AGA
AGA GAA GCT GGG GAA); CT-10 50 (50-GCA GAG TGG CCA
TTA TGG CCC CCT CCC GTT CCA GGC GTT CCA TTC) and
CT-10 30 (50-GCG GCC GAC ATG TTT TTT CCC TCA CTC
AGA AAA GGA GAC GTT GCT GG); SCP-1 fragment 1 (bp 1–
870) 50 (50-GAT AGG ATC CAT GGA AAA GCA AAA GCC CTT
TGC) and SCP-1 fragment 1 30 (50-ACT CGA GTA CCT GCT TTT
CCT TGT CAT TTA TTT CC); SCP-1 fragments 1/2 (bp 1–1623) 50
(50-GAT AGG ATC CAT GGA AAA GCA AAA GCC CTT TGC)
and SCP-1 fragments 1/2 30 (50-GAT ACT CGA GGT GTG AAG
TTA ATT CAG TAT TCT TAA GC); SCP-1 fragment 2 (bp 807–
1623) 50 (50-TAG GAT CCG TGC AAG CTG AGA ATT CCA
GAC TGG) and SCP-1 fragment 2 30 (50-ACT CGA GGT GTG
AAG TTA ATT CAG TAT TCT TAA GC); SCP-1 fragments 2/3
(bp 807–2415) 50 (50-TAG GAT CCG TGC AAG CTG AGA ATT
CCA GAC TGG) and SCP-1 fragments 2/3 30 (50-ACT CGA GTT
CTT TTG CCT CTC TTT TGA GTT TTT CC); SCP-1 fragments
3/4 (bp 1589–2995) 50 (50-TAG GAT CCA CAA GTG AAC AGT
ATT ATT CAA AAG AG) and SCP-1 fragments 3/4 30 (50-TAC
TCG AGA ACA AAT AAC TTT TCA GCT TCT TTT AG).
Because of its size, SCP-1 had to be divided into several frag-
ments, which were cloned into the BamH1/XhoI sites of pYD1.
NY-ESO-1-, MAGE-A3, SSX-2 and SSX-4 inserts were cloned into
the EcoRI/XhoI sites of pYD1. CT-7 and CT-10 were inserted by
homologous recombination. SSX-2 and SSX-4 primers are identi-
cal because of identical 50 and 30 cDNA sequence of SSX-2 and
SSX-4, respectively. All constructs were checked by sequencing.
The plasmids pYD1, pYD1-NY-ESO-1, pYD1-SSX-2, pYD1-
SSX4, pYD1-CT-7, pYD1-CT10 and pYD1-Mage-A3 as well as
the plasmids containing the 5 fragments of SCP-1 were introduced
into Saccharomyces cerevisiae EBY100 using a commercially
available transformation kit (EasyComp, Invitrogen) according to
the manufacturer’s recommendations. Thereafter, yeasts were
spread on MD-Leu plates (0.67% yeast nitrogen base, 2% dex-
trose, 0.01% leucine, 1.5% agar) for the selection of transformed
clones. Colonies were picked and cultured [YPD/CAA-Glu: 1%
yeast extract, 2% polypeptone, 2% dextrose; YNB/CAA-Glu: 2%
dextrose, 0.67% yeast nitrogen base, 0.5% Casamino acids (Difco,
Detroit, MI)] with constant agitation to an approximate OD
(600 nm) of 4 (30C, 4 hr). To induce surface protein expression,
yeasts were pelleted by centrifugation, resuspended to an OD
(600 nm) of 0.6 in YNB/CAA-Gal and grown with agitation for an
additional 48 hr (20C).
For preabsorption, sera were diluted 1:50 in PBS and mixed
with approximately 1/4 volume of pelleted yeast containing the
empty pYD1 vector. This preabsorption mix was agitated over-
night at 4C to eliminate unspeciﬁc binding to yeast surface mole-
cules. After pelleting, the supernatant was recovered and diluted
with PBS to a ﬁnal serum dilution of 1:100. Sodium azide (0.05%
w/v) was added for preservation.
Transformed and induced yeast cells were collected by centrifu-
gation (2,000g, 5 min) and washed with PBS. Yeasts containing
pYD1 as a control and yeasts containing pYD1 with the respective
antigenic inserts were incubated at room temperature with 100 ll
of preabsorbed serum (ﬁnal dilution 1:100) for 30 min with occa-
sional agitation. After washing with PBS (0.1% Tween), secon-
dary biotinylated antihuman IgG Fc-g-speciﬁc serum (Dianova,
Hamburg, Germany; dilution 1:200) was added and incubated for
30 min at room temperature with occasional agitation. Finally, R-
phycoerythrin-conjugated streptavidin (Dianova) was added (dilu-
tion 1:200, room temperature, 15 min) and washed twice with
PBS (0.1% Tween). Expression control for the cloned antigens
was performed by detection of expressed HIS-tag using the spe-
ciﬁc biotinylated anti-penta HIS antibody (1:500; Qiagen, Hilden,
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Germany) and R-phycoerythrin-conjugated streptavidin (dilution
1:200, 15 min incubation). Labeled yeast cell suspensions were
analyzed by ﬂow cytometry (FACScan; Becton Dickinson, Hei-
delberg, Germany). For each sample, 30,000 cells were collected.
The ratio between the intensity of the signal measured on antigen-
expressing and nonexpressing (pYD1) yeasts was calculated for
each individual serum sample. A sample was considered to be pos-
itive if this ratio was 2. All positive antibody reactivities were
conﬁrmed using the phage assay, as described before.13
Immunohistochemistry
Parafﬁn sections were deparafﬁnized in xylene and rehy-
drated in decreasing concentrations of ethanol. Following a
rinse with distilled water, endogenous peroxidase was quenched
with 3% hydrogen peroxide in methanol. Antigen was retrieved
by incubation in buffer (S2031; Dako-Cytomation, Glostrup,
Denmark) at 90–95C for 30 min. Unspeciﬁc binding sites
were blocked by incubation in 20% rabbit serum in TBS (v/v)
for 20 min. For detection of SCP-1, sections were incubated
for 30 min at 37C with a previously determined optimal dilu-
tion of mouse anti-SCP-1 MAb26 (SC554, IgG1; hybridoma
supernatant diluted 1:3 in TBS, 1% BSA, 0.1% Tween). For
detection of SSX, sections were incubated overnight at 4C
with mouse anti-SSX MAb reacting with SSX-2, SSX-3 and
SSX-4 but not SSX-1 (E3AS, IgG; hybridoma supernatant
diluted 1:2 in TBS, 1% BSA, 0.1% Tween).27 After washing
with TBS, slides were incubated with biotinylated rabbit anti-
mouse immunoglobulin antibody (1:200 in TBS, 1% BSA, 0.
1% Tween; E0413, Dako-Cytomation) for 15 min at 37C,
washed and incubated with horseradish peroxidase–conjugated
streptavidin complex (1:300 in TBS, 1% BSA, 0,1%Tween;
P0397, Dako-Cytomation) for 15 min at 37C. Sections were
sequentially washed. The color reaction was developed with
diaminobenzidine in TRIS-HCl buffer (3468, Dako-Cytomation)
and stabilized by saturated cupric sulfate for 2 min. Slides
were counterstained with Mayer’s hematoxylin. Nonspeciﬁc
staining of the primary antibody was assessed by substituting
an isotype-matched mouse myeloma antibody against an irrele-
vant protein (MOPC-21, IgG1; Sigma, Deisenhofen, Germany).
A consecutive section was stained by hematoxylin and eosin.
Positive control sections of testis were included with each
batch of staining.
Results
Study population and validity of the experimental approach
Expression of 11 CT genes (SCP-1, MAGE-3, MAGE-4, GAGE,
SSX-1, SSX-2, SSX-4, NY-ESO-1, CT-7, HOM-TES-85/CT-8 and
CT-10) was analyzed in 100 samples of fresh biopsies from pri-
mary breast cancer. With the exception of one case, all specimens
were proven to contain breast cancer tissue by routine histopatho-
logic evaluation of hematoxylin and eosin–stained slides. Another
sample was negative for p53 expression by RT-PCR and therefore
considered not evaluable for the expression studies, leaving a total
of 98 evaluable cases.
Intensities of PCR products were heterogeneous, and some
specimens yielded only faint amplicon bands. These were scored
positive only if the result could be reproduced by repeated RNA
extraction and speciﬁc PCR from the same tumor specimen with
clear bands. Cases with very low transcript levels in 2 experiments
and negative in a third test were not regarded as positive.
Complete clinical and immunohistologic data on 98 patients
treated by either breast-conserving surgery or mastectomy were
available (Table I). Median age was 59 years, with 28% in pre-
and 72% in postmenopause. According to the UICC classiﬁcation,
54% of patients had stage II invasive breast cancer and 32% had
stage I disease. Therefore, the majority of patients (86%) suffered
from early-stage invasive breast cancer (stages I and II), whereas
14% of patients were afﬂicted with locally advanced breast cancer
(stage III). Histopathologic analysis demonstrated invasive ductal
carcinoma in 73% of cases and invasive lobular carcinoma in
13%. The remaining 14% were diagnosed as mucinous, medul-
lary, tubular, intraductal, solid and cribriform carcinoma.
Expression of individual CT gene mRNA in primary
breast cancer
None of the 11 CT antigens studied was expressed in normal
breast tissue (n 5 4) or other normal tissues (bladder, brain, colon,
kidney, liver, lung, lymph node, muscle, ovary, peripheral blood
lymphocytes, prostate, rectum, skin, spleen, stomach, tonsil, ute-
rus). In contrast, primary breast cancers frequently expressed one
or more CT gene mRNA (Fig. 1). The most frequently expressed
CT genes were HOM-TES-14/SCP-1 and SSX-4, which were both
detected in 65% of cases, followed by HOM-TES-85/CT-8 (47%),
GAGE (26%), SSX-1 (20%), NY-ESO-1 (13%), MAGE-3 (11%),
SSX-2 (8%), CT-10 (7%),MAGE-4 (4%) and CT-7 (1%).
Coexpression of multiple CT gene mRNA in primary
breast cancer
Expression of at least one antigen was observed in 88 breast
cancer samples, and 77 cases expressed more than one CT gene
(Fig. 2). Three or more CT genes were expressed in 47 cases. Still
more than one-quarter (29%) expressed at least 4 CT genes, while
16 specimens expressed 5, 6 cases 6, 3 cases 7, 2 cases 8 and
one coexpressed 9 antigens. There was no obvious correlation
between the expression of different CT genes. While SCP-1 was
the most frequently expressed CT gene, of the 88 tumors that
expressed at least one CT gene, 25 were negative for SCP-1 and 6
did not express either of the 2 most frequently expressed genes,
SCP-1 and SSX-4.
Antibody reactivities against CT antigens in patients
with primary breast cancer
Sera from all of the 100 patients included in the study were
obtained at the day of breast surgery and tested for the presence of
antibodies against 7 CT antigens together with the sera of 50
healthy controls using RAYS: MAGE-3, SCP-1, SSX-2, SSX-4,
NY-ESO-1, CT-7 and CT-10. No antibodies were detected in the
sera of 50 healthy controls. Antibodies against NY-ESO-1 were
detected in the serum of 4 patients, against SCP-1 in 6 and against
SSX-2 in one patient; but no antibody reactivities were detected
against SSX-4, MAGE-3, CT-7 and CT-10. Three of 12 (25%)
TABLE I – PATIENT CHARACTERISTICS AND EXPRESSION OF
CT ANTIGENS
Characteristic Number of patients
Number of patients
with expression of a
CT gene mRNA




pT3–4 14 12 (86%)
pN status
pN0 50 44 (88%)
pN1 48 44 (92%)
Stage
0/I/II 84 76 (91%)
III/IV 14 12 (86%)
Grading
Moderately 301 26 (87%)
Poor 67 61 (91%)
Menopausal status
Premenopausal 27 24 (89%)
Postmenopausal 71 64 (90%)
Histology
Invasive ductal 72 65 (90%)
Invasive lobular 13 10 (77%)
Other2 13 13 (100%)
1No T stage and grading for one case with ductal carcinoma in situ.
–2See Results.
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patients with NY-ESO-1-positive tumors had detectable anti-NY-
ESO-1 antibody levels; in the tumor of the fourth anti-NY-ESO-1
antibody-positive patient, no NY-ESO antigen was detected on
repeated RT-PCR and immunohistologic analyses. Of the 63
patients with SCP-1-positive tumors, 6 (10%) had anti-SCP-1 anti-
body reactivity in their serum. The frequency of speciﬁc antibod-
ies in the serum of patients with SSX-2-positive tumors was simi-
lar (1/8% or 12.5%).
Expression of CT genes and correlation with
clinicopathologic parameters
Expression of each CT gene was correlated with the following 6
parameters: histology (ductal vs. lobular carcinoma); size of pri-
mary tumor (T1/2 vs. T3/4), presence or absence of lymph node
involvement (N0 vs. N1), grade of differentiation (2 vs. 3), meno-
pausal status (premenopausal vs. postmenopausal) and estrogen
receptor status. NY-ESO-1 was more often associated with lobular
than with ductal carcinoma (p 5 0.04, v2 test), MAGE-3 was more
often associated with larger primary tumors (T3,4; p 5 0.015, v2
test) and SCP-1 expression was more often associated with nodu-
lar involvement (p 5 0.03, v2 test) and estrogen receptor-negative
tumors (p 5 0.01, v2 test). However, when adapted for multiple
testing and a critical p value < 0.0083 (i.e., 0.05/G5 0.083), these
correlations did not retain clinical signiﬁcance.
SSX and SCP-1 protein expression
RT-PCR-positive breast carcinoma samples from which sufﬁ-
cient material was available were investigated for expression of
the frequently expressed SSX and SCP-1 proteins by immunohis-
tochemistry. Expression of SSX protein was found in 5 of 16 SSX
RT-PCR-positive tumor samples (31%). The staining pattern var-
ied from single positive cells to foci of positive cells distributed
all over the tumor. As shown in Figure 3, positive cancer cells
showed nuclear reactivity. Expression of SCP-1 antigen was dem-
onstrated in 6 of 13 SCP-1 RT-PCR-positive tumor samples
(46%) and revealed up to 50% single positive tumor cells per sam-
ple (Fig. 4). CT antigen-positive tumors, as demonstrated by
immunohistology, were found both in patients with and without
antibody reactivity against the respective antigen in their serum.
However, because the selection of tumors for immunohistology
was solely based on the availability of sufﬁcient biopsy material,
there was a bias toward larger tumors analyzed for protein expres-
sion. Due to this fact and the small number of appropriate biopsies
available, correlations of protein expression as demonstrated by
immunohistology with any of the clinical parameters listed in
Table I or the presence of antibodies in the serum of the respective
patients could not be investigated.
Discussion
To date, no systematic survey of CT gene expression and anti-
body responses against CT antigens in breast cancer patients has
been published. In our population of patients with early breast can-
cer, NY-ESO-1 was conﬁrmed as the most autoimmunogenic CT
antigen, with detectable antibody levels in one-quarter of patients
with NY-ESO-1-positive tumors. In contrast, the incidence of
SCP-1 and SSX-2 antibodies in patients with tumors expressing
the respective antigens was much lower, and antibodies against
the other 4 CT antigens expressed by the tumors were not
detected. The low incidence of antibodies to CT antigens in this
population might be interpreted as support for the widespread
assumption that the incidence of antibodies against CT antigens is
lower in patients with early-stage carcinoma than in patients with
a higher tumor load. However, this assumption is not based on
solid ground because no systematic studies addressing this ques-
tion have been published to date; rather, published reports are
mostly anecdotal and, therefore, no ﬁrm conclusions as to the fre-
quency of CT gene expression and antibody reactivity in the
serum of patients with low vs. high tumor load can be drawn. We
cannot exclude the possibility that CT antigen expression and anti-
body frequencies might be quite different in metastatic disease;
however, there is no published study that prospectively compared
CT antigen expression and antibody reactivity in limited-stage and
metastatic disease. A previous smaller (and retrospective) study
performed by our group in a different series of patients that also
included patients with metastatic disease28 yielded frequencies of
SSX and SCP-1 expression and antibodies against these CT anti-
gens that were quite similar to the ones reported here.
Antibodies against CT antigens were detected only in patients
with tumors expressing the respective CT gene mRNA but not in
patients with CT gene-negative tumors or healthy controls. The
only exception to this was the detection of NY-ESO-1 antibodies
in the serum of one patient with an NY-ESO-1-negative tumor.
This case was checked again for NY-ESO-1 expression by RT-
PCR using 2 different primer pairs, and NY-ESO-1 negativity was
conﬁrmed. The presence of speciﬁc IgG antibodies in the absence
of NY-ESO-1 expression might be explained by a recent report,
where NY-ESO-1 was found in 68% of ﬁbroadenomas and ﬁbro-
cystic disease cases.29
The physiologic function of most CT genes is unknown, and
their possible role in tumorigenesis can only be speculated.30,31
The CT gene with the most frequent expression in breast carci-
noma was that coding for HOM-TES-14/SCP-1, which is involved
in meiotic chromosome pairing.32 SCP-1 is also frequently found
(30–50%) in other neoplasms, including gastrointestinal cancers
like colorectal and gastric carcinomas,20 hepatocellular carcino-
mas,24 breast carcinomas,20 astrocytomas,26 lymphomas33 and
pancreatic carcinomas.23 The function of SSX-4, the other CT gene
found in a signiﬁcant proportion of breast carcinomas, is not
known. Expression of the other CT genes investigated in our study
FIGURE 1 – Frequency of CT gene expression in primary breast car-
cinoma. The proportion of RT-PCR-positive cases is shown as a per-
centage of 98 evaluable breast carcinoma samples.
FIGURE 2 – Simultaneous expression of multiple CT antigens in pri-
mary breast cancer. The proportion of breast carcinomas expressing at
least one and up to 10 CT antigens is shown as a percentage of 98
samples.
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FIGURE 3 – Immunohistologic detection of SSX by MAb E3AS in an invasive ductal carcinoma of the breast. Positive cancer cells show
nuclear reactivity and appear scattered in different regions of the tumor. Immunoperoxidase stain, DAB; 3200 magniﬁcation.
FIGURE 4 – Immunohistologic detection of SCP-1 by MAb SC554 in an invasive ductal carcinoma of the breast. Positive cancer cells show
cytoplasmic reactivity in 20–50% of tumor cells. Immunoperoxidase stain, DAB; 3400 magniﬁcation.
was infrequent. Results concerning their expression have not been
published to date for breast cancer. SCP-1 has also been reported
by others to be the most frequently expressed CT antigen in breast
carcinomas.20 Expression of the MAGE antigens in our study was
in a range similar to what has been described in another study
restricted to analysis of MAGE antigens,34 while it was reported
to be higher in poorly differentiated breast cancers.35
Reports on the association of CT gene expression with clinical
parameters must be met with caution because the associations are
usually weak and the signiﬁcance levels not adjusted for multiple
testing. This also applies to the reported correlation of NY-ESO-1
T-cell responses with antibody responses,36 which could not be
conﬁrmed by others.37 In another study, NY-ESO-1 was associated
with higher histologic grade (p 5 0.097) and negative estrogen
receptor status (p 5 0.082). MAGE immunoreactivity was inver-
sely correlated with tumor differentiation in yet another study.35
In our study, we observed trends (p < 0.05) for an association
between NY-ESO-1 and lobular rather than ductal carcinoma,
MAGE-3 and large primary tumors (T3,4) as well as higher histo-
logic grade and SCP-1 and the absence of estrogen receptors in
the tumor and nodular involvement; however, after adjusting for
multiple testing, these correlations failed to reach the adjusted sig-
niﬁcance level of p < 0.0083 (i.e., p < 0.05/G 5 0.083 for testing
6 clinical parameters). Even if the prognostic subgroups of patients
in Table I were large enough to yield statistically signiﬁcant dif-
ferences, the ﬁgures in Table I make it clear that such differences
would be in the range of a few percent only.
Whether immunologic factors play a role in the pathogenesis of
human breast cancer is still a matter of debate. Lymphoid inﬁl-
trates are frequent in breast cancer,38–40 particularly the intense B-
and T-cell inﬁltrates in medullary carcinoma,41,42 and suggest that
there is immune recognition in breast cancer; however, there is as
yet no conclusive evidence that such inﬁltrates have prognostic
value.43 From our data, it becomes evident that 90% of our
patients with primary breast carcinoma would be eligible for spe-
ciﬁc immunotherapeutic approaches with at least one CT antigen,
nearly two-thirds would be eligible for a bivalent CT antigen vac-
cin, and for nearly half a trivalent vaccine would be available.
This makes primary breast cancer one of the human neoplasms
with the most frequent expression of CT genes. Several phase I
studies using various vaccine strategies similar to those previously
evaluated in malignant melanomas44–46 have suggested the safety
of this approach in breast cancer patients47 and other types of
human cancer.48 As a note of caution, however, one should keep
in mind that SCP-1 and SSX expression at the protein level could
be demonstrated not in all cases expressing the respective mRNA.
Whether this is due to a lower sensitivity of the detection method
used (immunohistology using CT antigen-speciﬁc antibodies) or
whether the mRNA is not translated into protein cannot be deter-
mined at this point. The fact that we detected SCP-1 antibodies in
patients with SCP-1 mRNA-positive tumors that were negative on
immunohistology suggests that the failure to detect the antigenic
protein is rather due to sensitivity problems of the immunohisto-
logic method. It also shows that mRNA-positive tumors can elicit
immune responses even if the speciﬁc protein expression is below
the immunohistologic detection level. However, even if small
amounts of protein can elicit speciﬁc IgG antibody responses in a
cancer patient, it remains to be shown whether antigen expression
that is below the detection limit by immunohistology can render a
tumor cell a target of a successful cytotoxic immune attack. Our
study shows that the demonstration of expression of cancer-spe-
ciﬁc antigens by tumor cells is only an important ﬁrst step on the
long road to the development of a clinically successful vaccine for
breast cancer.
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